On 19 Nov 2025, the company’s Mojo Score was recorded at 44.0, with a corresponding grade adjustment noted the previous day. This change is primarily attributed to shifts in the technical grade, which moved from mildly bearish to bearish, signalling a more cautious outlook from a market momentum perspective. Rossari Biotech’s market capitalisation grade remains at 3, reflecting its mid-tier positioning within the Specialty Chemicals industry.
Examining the technical parameters in detail, the Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture: weekly data suggests a mildly bullish stance, whereas monthly readings indicate bearish momentum. The Relative Strength Index (RSI) shows no definitive signal on a weekly basis but registers bullish tendencies monthly. Bollinger Bands, a volatility measure, are bearish on both weekly and monthly timeframes, while daily moving averages also align with a bearish trend. Additional technical tools such as the Know Sure Thing (KST) indicator and Dow Theory provide mixed signals, with weekly data leaning mildly bullish or bearish and monthly data generally lacking a clear trend. The On-Balance Volume (OBV) indicator similarly reflects mild bearishness weekly but no discernible trend monthly.
Price action for Rossari Biotech on the day of the evaluation adjustment saw the stock close at ₹626.45, down from the previous close of ₹630.45. The day’s trading range was between ₹623.55 and ₹631.00, with the 52-week high and low recorded at ₹883.00 and ₹568.05 respectively. This price behaviour underscores the stock’s current consolidation phase within a broader downtrend.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- Early turnaround signals
- Explosive growth potential
- Textile - Machinery recovery play
Position for Explosive Growth →
From a returns perspective, Rossari Biotech has underperformed relative to the Sensex benchmark across multiple time horizons. Over the past week, the stock declined by 0.39%, whereas the Sensex gained 0.96%. The one-month return for Rossari Biotech was -6.61%, contrasting with a 0.86% rise in the Sensex. Year-to-date figures reveal a 20.47% reduction in the stock’s value, while the Sensex advanced by 8.36%. Over the last year, Rossari Biotech’s return was -19.18%, compared to the Sensex’s 9.48% gain. Longer-term data over three and five years also show the stock lagging significantly behind the benchmark, with returns of -22.27% and -20.28% respectively, against Sensex returns of 37.31% and 91.65%. Ten-year data for Rossari Biotech is not available, but the Sensex’s 232.28% gain over this period highlights the broader market’s growth trajectory.
Financially, the company reported flat performance in the second quarter of fiscal year 2025-26. Interest expenses for the nine-month period stood at ₹17.32 crores, reflecting a growth rate of 40.70%. The operating profit to interest ratio for the quarter was at a low of 11.81 times, indicating tighter coverage of interest obligations. Dividend payout ratio on a yearly basis was recorded at 2.41%, one of the lowest in recent periods. These figures suggest a cautious financial trend with limited expansion in profitability and cash returns to shareholders.
Rossari Biotech’s debt profile remains conservative, with an average debt-to-equity ratio of 0.07 times, signalling minimal leverage. Return on Capital Employed (ROCE) stands at 13.2%, which, coupled with an enterprise value to capital employed ratio of 2.4, points to an attractive valuation relative to its capital base. The stock’s valuation metrics are broadly in line with historical averages for its peer group, indicating a fair price level in the context of sector norms.
Profitability trends over the past year show a marginal decline, with profits falling by 1.5%. Institutional investors hold a significant stake of 20.87%, reflecting confidence from entities with substantial analytical resources and long-term investment horizons. This institutional presence may provide some stability amid the stock’s recent performance challenges.
Is Rossari Biotech your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- Better alternatives suggested
- Cross-sector comparison
- Portfolio optimization tool
In summary, the adjustment in Rossari Biotech’s evaluation reflects a complex interplay of factors. The technical indicators predominantly signal caution, with bearish trends evident in key momentum and volatility measures. Financially, the company’s flat quarterly results and rising interest expenses suggest limited operational expansion, while valuation metrics remain reasonable within the sector context. The stock’s consistent underperformance relative to the Sensex and BSE500 over recent years further contextualises the revision in its score.
Investors analysing Rossari Biotech should consider these multifaceted elements, balancing the company’s conservative debt position and institutional backing against the subdued returns and technical signals. This comprehensive view aids in understanding the rationale behind the recent call changes and provides a foundation for informed decision-making in the Specialty Chemicals sector.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
